AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03792685 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High-fat meal intake
Description: Subjects are going to receive the high-fat meal.
Study NCT03792685 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High-protein meal intake
Description: Subjects are going to receive the high-protein meal.
Study NCT04181918 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: AOT
Description: During action observation, participants observe different daily actions (e.g. reading a newspaper; drinking an espresso) divided into up to four motor segments.
Study NCT04181918 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MI
Description: During motor imagery, participants imagine themselves performing the same daily actions as in AOT in the absence of motor output
Study NCT02102139 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DXM + Propofol
Description: After induction as mentioned at 'arm description', the effect-site propofol concentration was fixed at 5.0 μg mL-1 at the time of diluted epinephrine injection and was unchanged during the entire hydrodissection period in all patients.~The first patients received effect-site concentrations of remifentanil of 4 ng mL -1, respectively. The EC50 of remifentanil for stable hydrodissection was determined by a modification of Dixon's up-and-down method.If the response was success (SBP during the entire hydrodissection period being ±20% from baseline), the next target concentration of remifentanil was decreased by a step of 0.5 ng mL -1. If the response was fail(SBP > ±20% from baseline), the target concentration was increased by 0.5 ng mL-1.
Study NCT02102139 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline + Propofol
Description: All procedure would be same in DXM+Propofol group except saline loading rather than DXM loading before induction.
Study NCT03560713 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Functional Electrical Stimulation (FES)
Description: Participants will perform 12 weeks of FES (Neurodyn High Volt, IBRAMED, São Paulo/SP, Brasil), three times a week, frequency 25Hz, pulse rate of 200μs, ON:OFF 5:5, individual maximum tolerated intensity; minimum at strong but comfortable visible muscle contraction (without causing undue pain or discomfort to the participant). during 30 minutes nd receive aerobic exercise training and resistance exercises for upper limbs and lower limbs.
Study NCT03560713 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Functional Electrical Stimulation (FES) sham
Description: Participants will perform 12 weeks of Functional Electrical Stimulation (FES) sham (Neurodyn High Volt, IBRAMED, São Paulo/SP, Brasil), three times a week, frequency 5Hz, pulse rate of 200μs, ON:OFF 5:5, without muscle contraction during 30 minutes nd receive aerobic exercise training and resistance exercises for upper limbs and lower limbs.
Study NCT04139785 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Moodbuster
Description: Moodbuster intervention comprises three elements: (1) a web-based interface providing the patients access to CBT therapies, (2) a web-based portal for the trial co-ordinator and researchers, where they can view participation, amend modules and send login codes, (3) a mobile phone component which enables daily EMA monitoring of mood state, cognitions, activities, social interaction, and sleep.~The mobile application will be used to capture EMA data.
Study NCT04720859 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Canagliflozin 300 MG Oral Tablet
Description: Patients diagnosed with PHH following bariatric surgery by 100g glucose OGTT were prescribed 300mg canagliflozin during two weeks. 100g glucose OGTT response was evaluated after canagliflozin treatment.
Study NCT01485601 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: MT10109
Description: Single dose intramuscular injection MT10109 vs Botox®
Study NCT01485601 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MT10109
Description: Single dose intramuscular injection MT10109 vs Botox®
Study NCT00955929 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sildenafil and questionnaire
Description: Patients will be instructed to take sildenafil 50 mg QHS (blinded) except on nights that they are interested in sexual relations, they will then be instructed to use sildenafil 100mgs (open-label) and skip the 50mg dose. Sildenafil treatment will start within 24-48 hours post-surgery. Patients will be evaluated in the clinic and will complete the questionnaires at baseline (pre-treatment evaluation), 3, 6, 9, 12, 18 and 24 months after the operation. At 12 months postoperatively, all patients will stop treatment. Visits 3, 6, 9, 12, 18, and 24 months will have ±2 week window
Study NCT00955929 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trimix combination (Papavarine 30mg/mL Phentholamine 1mg/mL Prostaglandin E1 10 mcg/mmL) and questionnaires
Description: Intracavernous injections of a trimix combination (Papaverine 30mg/mL Phentholamine 1mg/mL Prostaglandin E1 10 mcg/mL) will be injected three times a week, and sildenafil 50mg taken on the other four (non-injection) nights. Injection therapy can be used for the purpose of sexual relations. Patients will be evaluated in the clinic and will complete the questionnaires at baseline (pre-treatment evaluation), 3, 6, 9, 12, 18 and 24 months after the operation. At 12 months postoperatively, all patients will stop treatment. Visits 3, 6, 9, 12, 18, and 24 months will have ±2 week window.
Study NCT04382599 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Text warning with octagon background
Description: The warning message is in white text on a black octagon background
Study NCT02390583 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CBT treatment of internet dependence
Description: CBT treatment of internet dependence
Study NCT02390583 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CBT treatment of internet dependence
Description: CBT treatment of internet dependence
Study NCT02390583 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CBT treatment of sleep disorders
Description: CBT treatment of sleep disorders
Study NCT03603795 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eltrombopag
Description: Eltrombopag concomitant with induction chemotherapy in patient with AML
Study NCT03603795 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo concomitant with induction chemotherapy patients with AML
Study NCT01844635 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thymoglobulin
Study NCT01844635 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Thymoglobulin
Study NCT01427296 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Polyethylene glycol
Description: HalfLytely and Bisacodyl Tablet Bowel Prep Kit, administered as 1 bisacodyl tablet followed by HalfLytely oral solution in a total liquid volume of approximately 2 L
Study NCT01427296 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral sodium phosphate solution
Description: OsmoPrep tablets (48 g), administered as 32 total tablets in a total liquid volume of approximately 2 L
Study NCT02665975 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CBT-based internet-intervention for tinnitus
Description: Tinnitus e-learning programme
Study NCT02665975 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Face-to-face clinical tinnitus care
Description: Hospital tinnitus counselling
Study NCT00958880 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Group Cognitive Behavioral Therapy
Description: 5 weeks of group CBT for Social Anxiety. The aim of CBT is to help participants become more comfortable with social situations~One arm will receive placebo augmented Group Cognitive Behavioral Therapy and the other will receive yohimbine hydrochloride augmented cognitive behavioral therapy.
Study NCT00958880 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group Cognitive Behavioral Therapy
Description: 5 weeks of group CBT for Social Anxiety. The aim of CBT is to help participants become more comfortable with social situations~One arm will receive placebo augmented Group Cognitive Behavioral Therapy and the other will receive yohimbine hydrochloride augmented cognitive behavioral therapy.
Study NCT00958880 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Yohimbine Hydrochloride
Description: Participants in the Yohimbine augmented arm will receive 4 doses of Yohimbine Hydrochloride before 4 of the 5 group cognitive behavioral therapy sessions.
Study NCT00958880 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sugar Pill
Description: Participants in the placebo (sugar pill) augmented arm will receive 4 doses of a sugar pill before 4 of the 5 group cognitive behavioral therapy sessions.
Study NCT01342562 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: spinal anesthesia
Description: 0.4% bupivacaine(normal saline 0.3ml with dexmedetomidine 3 mcg)
Study NCT01342562 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: spinal anesthesia
Description: 0.4% bupivacaine(normal saline 0.3 ml with 0.5% bupivacaine 1.2 ml)
Study NCT02451566 — intervention group
Intervention type: DEVICE
Intervention: Ovation Prime Abdominal Stent Graft System
Study NCT01544972 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral paracetamol
Description: Patients will receive oral paracetamol 15 mg/kg per dose every 6 hours.
Study NCT01544972 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral ibuprofen
Description: Patients will receive oral ibuprofen at an initial dose of 10 mg/kg, followed by 5 mg/kg at 24 and 48 h.
Study NCT04380207 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QPX7728
Description: antibiotic
Study NCT04380207 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo comparator
Study NCT04380207 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QPX2014
Description: antibiotic
Study NCT04507958 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: auscultation by using conventional stethoscope without PPE
Description: In thoracic patients undergoing general anesthesia with endotracheal tube/endobronchial blocker, Clinician will check the position of endotracheal tube and endobronchial blocker under fiberscope. Afterward, investigator A will perform auscultation with traditional auscultation, then investigator B with electronic stethoscope under full PPE, to examine bilateral breathing sound.
Study NCT04507958 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: auscultation by using electronic stethoscope in full PPE
Description: In thoracic patients undergoing general anesthesia with endotracheal tube/endobronchial blocker, Clinician will check the position of endotracheal tube and endobronchial blocker under fiberscope. Afterward, investigator A will perform auscultation with traditional auscultation, then investigator B with electronic stethoscope under full PPE, to examine bilateral breathing sound.
Study NCT00700011 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clofarabine
Description: 10 mg/m2 x 5 days per 4 to 6 week cycles
Study NCT00700011 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clofarabine
Description: 5 mg/m2 x 5 days per 4 to 6 week cycles
Study NCT03419091 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: single-use flexible digital ureteroscope
Description: Device being tested.
Study NCT03419091 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Reusable Ureteroscope
Description: Comparative device.
Study NCT03354494 — intervention group
Intervention type: DRUG
Intervention: Desogestrel (DSG) and Corifolitropin (FSH-CTP) Alfa
Study NCT04449367 — intervention group
Intervention type: PROCEDURE
Intervention: ultrasound guided erector spinae plane block
Description: bilatral block given to patients under general anaesthesia for thoracic spine sugery to contorl post operative pain
Study NCT01900613 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Ninos Sanos Familia Sana
Study NCT01900613 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Ninos Sanos Familia Sana
Study NCT01067703 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Remote Ischemic Preconditioning
Description: RIPC will be induced during anesthesia by four 5-min cycles of upper limb ischemia and 5-min reperfusion using a blood-pressure cuff inflated to a pressure 200 mm Hg, whereas the pressure has to be at least 20 mm Hg greater than the systolic arterial pressure measured via the arterial line.
Study NCT01067703 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Control/sham procedure (blood pressure cuff)
Description: Sham placement of the blood pressure cuff around a dummy arm inflated to a pressure of 200 mm Hg with four cycles of 5 min inflation and 5 min deflation.
Study NCT03069027 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: External nasal nerve block
Description: Three single (midline injection) and 4 paired (bilateral injection) sites to block the external nasal sensation.
Study NCT03069027 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: External nasal nerve block
Description: Three single (midline injection) and 4 paired (bilateral injection) sites to block the external nasal sensation.
Study NCT03069027 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: saline adrenaline
Study NCT03069027 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Xylocaine, adrenaline
Study NCT01941953 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin and Fluorouracil
Description: metformin 850mg PO BID plus 5FU 425mg/m2 + leucovorin 50mg IV weekly
Study NCT02006238 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Farabloc
Description: The participants will be randomly received Farabloc (experimental) for one week, followed by a 7 day washout and then crossed over to received the Nylon fabric (placebo) for one week.
Study NCT02006238 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Farabloc
Description: The participants will be randomly received Farabloc (experimental) for one week, followed by a 7 day washout and then crossed over to received the Nylon fabric (placebo) for one week.
Study NCT02006238 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nylon Fabric
Description: The participants will be randomly received Nylon fabric (placebo) for one week, followed by a 7 day washout and then crossed over to receive Farabloc (experimental) for one week.
Study NCT02006238 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Nylon Fabric
Description: The participants will be randomly received Nylon fabric (placebo) for one week, followed by a 7 day washout and then crossed over to receive Farabloc (experimental) for one week.
Study NCT05447949 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Adjuncts to levobupivacaine in Erector Spinae Plane Block
Description: The block level will be at T5 with the patient in a sitting position and full aseptic precautions. T5 transverse process; these are recognizable as flat, squared-off acoustic shadows with only a very faint image of the pleura visible. In a longitudinal US view, in which the following layers will be visible superficial to the transverse processes: skin, subcutaneous tissue, trapezius, erector spinae muscle . Skin is topicalized, then echogenic block needle inserted in plane to the ultrasound beam in a cranial-to-caudal direction until contact is made with the T5 transverse process. After aspiration; to avoid intravascular injection, 30 ml of injectate is injected and separation will be seen. 6-13-MHz, linear transducer set for small parts and a depth of 4-6 cm will be used (18-19).
Study NCT05447949 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Adjuncts to levobupivacaine in Erector Spinae Plane Block
Description: The block level will be at T5 with the patient in a sitting position and full aseptic precautions. T5 transverse process; these are recognizable as flat, squared-off acoustic shadows with only a very faint image of the pleura visible. In a longitudinal US view, in which the following layers will be visible superficial to the transverse processes: skin, subcutaneous tissue, trapezius, erector spinae muscle . Skin is topicalized, then echogenic block needle inserted in plane to the ultrasound beam in a cranial-to-caudal direction until contact is made with the T5 transverse process. After aspiration; to avoid intravascular injection, 30 ml of injectate is injected and separation will be seen. 6-13-MHz, linear transducer set for small parts and a depth of 4-6 cm will be used (18-19).
Study NCT04382599 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Icon warning
Description: The warning message in in white text on a black background, below an icon that conveys the topic the warning is about
Study NCT01282424 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Idelalisib
Description: Idelalisib 150 mg tablet administered orally twice daily
Study NCT00573963 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ropivacaine
Description: 2 injections of 20mL 0.375% ropivacaine - one given on each side.
Study NCT00573963 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: saline solution
Description: 2 injections of 20mL plain saline solution - one on each side.
Study NCT02268981 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Oxymizer® compared to CNC
Description: Oxygen Saturation measurement for 12 h with CNC
Study NCT02268981 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Oxymizer® compared to CNC
Description: Oxygen Saturation measurement for 12 h with Oxymizer®
Study NCT02268981 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Oxymizer® compared to CNC
Description: Saturation measurement for 12 h with Oxymizer® by reduced flow rate (-1l/min)
Study NCT00338195 — intervention group
Intervention type: BEHAVIORAL
Group type: NO_INTERVENTION
Intervention: Individualized caffeine cessation instructions
Description: Intervention is described in the protocol
Study NCT04382599 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Icon warning
Description: The warning message in in white text on a black background, below an icon that conveys the topic the warning is about
Study NCT04382599 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Graphic warning
Description: The warning message in in white text on a black background, below a graphic that conveys the topic the warning is about
Study NCT04382599 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Graphic warning
Description: The warning message in in white text on a black background, below a graphic that conveys the topic the warning is about
Study NCT03315325 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Human kisspeptin-10 (metastin 45-54)
Description: Kisspeptin-10 (metastin 45-54, Calbiochem, Darmstadt, Germany) is a potent HPG-axis stimulator and control reproduction.
Study NCT01130805 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pazopanib in combination with capecitabine and oxaliplatin
Description: Capecitabine 850 mg/m2 bid on day 1-14, Oxaliplatin 130 mg/m2 IV on day 1 and Pazopanib 800 mg once in a day on day 1-21, every 3 weeks
Study NCT05041179 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Pruvin R
Description: Combination of N-acetylcysteine an glycine
Study NCT03586284 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Valganciclovir Hydrochloride
Description: 21 to 28 days of oral valganciclovir treatment
Study NCT03586284 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ganciclovir Sodium
Description: 21 to 28 days of topical ganciclovir solution treatment
Study NCT03586284 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: 21 to 28 days of placebo pill treatment
Study NCT03586284 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo Oral Tablet
Description: 21 to 28 days of placebo pill treatment
Study NCT03586284 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Topical placebo
Description: 21 to 28 days of topical placebo treatment
Study NCT03586284 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Topical placebo
Description: 21 to 28 days of topical placebo treatment
Study NCT05041179 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Isomaltulose
Description: Placebo as comparator to intervention
Study NCT04032522 — intervention group
Intervention type: OTHER
Intervention: point-of care (PoC) neonatal HIV early infant diagnosis (EID)
Description: clinical impact of a PoC-EID for infants and neonates at birth and week 4-8 weeks, linked with nurse-supported immediate ART initiation in HIV-infected neonates, versus standard-of-care (SoC)
Study NCT03555526 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esomeprazole 40mg
Description: Nexium (esomeprazole), 40mg, bid, for 14 days
Study NCT03555526 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Esomeprazole 40mg
Description: Nexium (esomeprazole), 40mg, bid, for 14 days
Study NCT03555526 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amoxicillin
Description: amoxicillin, 1000mg, bid, for 7 days (day 1-day 7)
Study NCT03555526 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amoxicillin
Description: amoxicillin, 1000mg, bid, for 7 days (day 1-day 7)
Study NCT03555526 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: metronidazole
Description: metronidazole, 500mg, bid, for 7 days (day 8-14)